Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes.


Journal

Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 29 06 2022
revised: 28 10 2022
accepted: 02 12 2022
pubmed: 7 12 2022
medline: 3 1 2023
entrez: 6 12 2022
Statut: ppublish

Résumé

Bile acid (BA) homeostasis is a complex and precisely regulated process to prevent impaired BA flow and the development of cholestasis. Several reactions, namely hydroxylation, glucuronidation and sulfation are involved in BA detoxification. In the present study, we employed a comprehensive approach to identify the key enzymes involved in BA metabolism using human recombinant enzymes, human liver microsomes (HLM) and human liver cytosol (HLC). We showed that CYP3A4 was a crucial step for the metabolism of several BAs and their taurine and glycine conjugated forms and quantitatively described their metabolites. Glucuronidation and sulfation were also identified as important drivers of the BA detoxification process in humans. Moreover, lithocholic acid (LCA), the most hydrophobic BA with the highest toxicity potential, was a substrate for all investigated processes, demonstrating the importance of hepatic metabolism for its clearance. Collectively, this study identified CYP3A4, UGT1A3, UGT2B7 and SULT2A1 as the major contributing (metabolic) processes in the BA detoxification network. Inhibition of these enzymes by drug candidates is therefore considered as a critical mechanism in the manifestation of drug-induced cholestasis in humans and should be addressed during the pre-clinical development.

Identifiants

pubmed: 36473578
pii: S0887-2333(22)00231-4
doi: 10.1016/j.tiv.2022.105533
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
Cytochrome P-450 CYP3A EC 1.14.14.1
Glucuronosyltransferase EC 2.4.1.17

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105533

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None of the authors has any conflict of interest to this study to declare.

Auteurs

Vlasia Kastrinou Lampou (V)

Department of Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland; Department of Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Birk Poller (B)

Department of Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Felix Huth (F)

Department of Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Audrey Fischer (A)

Department of Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Gerd A Kullak-Ublick (GA)

Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis, Basel, Switzerland.

Michael Arand (M)

Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.

Heiko S Schadt (HS)

Department of Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Gian Camenisch (G)

Department of Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland. Electronic address: gian.camenisch@novartis.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH